FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Quinoline topics
Isoquinolin
Praziquantel
Carbon Atoms
Crystallin
Quinoline Derivatives
Pharmaceutically Acceptable Salt
Alkyl Group
Cycloalkyl
Pharmaceutically Acceptable Salts
Immunodeficiency
Retrovirus
Viral Infection
Human Immunodeficiency Virus
Angiogenesis
Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Quinoline patents



      
           
This page is updated frequently with new Quinoline-related patent applications. Subscribe to the Quinoline RSS feed to automatically get the update: related Quinoline RSS feeds. RSS updates for this page: Quinoline RSS RSS


Date/App# patent app List of recent Quinoline-related patents
07/17/14
20140200346
 Novel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline patent thumbnailNovel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
The present invention provides a new process of synthesis of a polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline of formula i. Said quinoline compound is substantially pure of any impurities.
07/17/14
20140200242
 Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds patent thumbnailProcesses for preparing quinoline compounds and pharmaceutical compositions containing such compounds
The present invention is directed to processes for making and compositions containing quinolines such as formula i or pharmaceutically acceptable salts thereof wherein: x1 is h, br, ci, or x2 is h, br, ci, or n1 is 1-2; and n2 is 1-2.. .
07/17/14
20140200222
 N-linked quinolineamide m1 receptor positive allosteric modulators patent thumbnailN-linked quinolineamide m1 receptor positive allosteric modulators
The present invention is directed to n-linked quinoline amide compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
07/10/14
20140194435
 Novel substituted indolo 4,3 fg quinolines useful for treating migraine patent thumbnailNovel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/10/14
20140194434
 Novel substituted indolo 4,3 fg quinolines useful for treating migraine patent thumbnailNovel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/03/14
20140187787
 Process for preparing modulators of cystic fibrosis transmembrane conductance regulator patent thumbnailProcess for preparing modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to processes for preparing solid state forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including compound 1 form a, compound 1 form a-hcl, compound 1 form b, and compound 1 form b-hcl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.. .
07/03/14
20140187785
 Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine patent thumbnailProcess for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
Wherein r2, r3, r4 and prot are as defined in the specification.. .
07/03/14
20140187547
 Azaindenoisoquinoline topoisomerase i inhibitors patent thumbnailAzaindenoisoquinoline topoisomerase i inhibitors
The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase i, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.. .
07/03/14
20140186965
 Methods to dissolve beryllium and its compounds present in samples to facilitate determination of beryllium in these samples patent thumbnailMethods to dissolve beryllium and its compounds present in samples to facilitate determination of beryllium in these samples
A safer, low-cost practical method of dissolving beryllium or a beryllium compound including beryllium oxide in a sample is disclosed. This method discloses use of acidic solutions under mild heating conditions to dissolve beryllium and its compounds.
07/03/14
20140186280
 Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof patent thumbnailNeuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
8-hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective mao-ab inhibitory activities.. .
07/03/14
20140183503
Light-emitting element, light-emitting device, electronic appliance, and lighting device
Disclosed is a light-emitting element having high emission efficiency, capable of driving at low voltage, and showing a long lifetime. The light-emitting element contains a compound between a pair of electrodes, and the compound is configured to give a first peak of m/z around 202 and a second peak of m/z around 227 in a mass spectrum.
07/03/14
20140183413
Quinoline-benzoxazole derived compounds for electronic films and devices
Or a combination thereof (c). For each formula, the r groups are described herein..
06/26/14
20140179923
New ligands of the benzo[h]quinoline class and transition metal complexes containing them and use of said complexes as catalysts
A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group viii transition metals iron, ruthenium or osmium, with the benzo[h]quinoline ligands acting as tridentate ligands.
06/26/14
20140178316
Skin treatments containing pyrroloquinoline quinone (pqq) esters and methods of preparation and use thereof
The present invention relates to cosmetic or dermatological compositions containing pqq or its esters, methods of treating or promoting skin changes by topical application of these compositions, and methods of synthesis of pqq esters. The pqq ester-containing compositions of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance.
06/26/14
20140175406
Phosphorescent compounds and organic light emitting diode devices using the same
Where x, y, and z are each selected from the group consisting of carbon and nitrogen, and when x, y, and z are all carbon, r is any one selected from the group consisting of carbazole, α-carboline, β-carboline, γ-carboline, fluorine, dibenzothiophene, dibenzofuran, triphenylsilane, tetraphenylsilane, pyridine, quinoline, isoquinoline, pyrimidine, diphenylphosphineoxide, and substituents thereof.. .
06/19/14
20140171462
4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
06/19/14
20140171384
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. Hki-272, ski-606, ekb-569) and a capecitabine compound in the treatment of a neoplasm is provided.
06/12/14
20140163068
Pharmaceutical compositions for the treatment of cftr mediated diseases
Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound 1) in form i and a solid dispersion comprising substantially amorphous n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide (compound 2), methods of treating, lessening the severity of, or symptomatically treating cftr mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.. .
06/05/14
20140155610
Preparation of pyridonecarboxylic acid antibacterials
1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.. .
06/05/14
20140155396
C-met modulators and method of use
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-met, kdf, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
06/05/14
20140154272
Compound and method for modulating opioid receptor activity
The invention provides a compound of formula (i), wherein r1 is h, c(nh)nh2, an amino acid, or a peptide; x is oh, nh2, nhr2, nr2r3, an amino acid, or a peptide; r2 and r3 are selected from alkyl, alkylenearyl, or alkyleneheteroaryl; each r4 and r5 is independently h or ch3; z is 2-amino-2,3-dihydro-1h-indene-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6-amino-6,7,8,9-tetrahydro-5h-benzo[7]annulene 6-carboxylic acid; cyclohexylalanine; cyclohexylglycine; homophenylalanine; 1-naphthylalanine; 2-naphthylalanine; 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or octahydro-1h-indole-2-carboxylic acid; n is 0, 1, 2, 3, or 4; with the proviso that x is not nh2 when r1 is h, r4 is h, r5 is ch3, z is aci, and n is 2; or a pharmaceutically acceptable salt, ester or solvate thereof. A method of treating pain and a method for treating a mu-opioid receptor mediated disorder and/or a delta-opioid receptor mediated disorder also are provided..
05/29/14
20140148478
Heteroquinoline-3-carboxamides as kcnq2/3 modulators
The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.. .
05/22/14
20140142312
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
The present invention relates to crystalline solvate forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith..
05/22/14
20140142138
Pharmaceutical compositions and administrations thereof
The present invention relates to the use of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of cftr mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.. .
05/08/14
20140128609
Pyrroloquinoline quinone disodium salt crystal and method for producing the same
An object of the present invention is to provide a novel pyrroloquinoline quinone disodium crystal having excellent dispersibility in solvents and excellent permeability through skin, and a method for producing the pyrroloquinoline quinone disodium crystal with high efficiency. According to the present invention, provided are a novel pyrroloquinoline quinone disodium crystal which is produced by drying a crystal produced under specified conditions through a drying means such as lyophilization, ambient drying and vacuum drying, and a method for producing the pyrroloquinoline quinone disodium crystal..
05/08/14
20140128367
Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
The invention provides certain cycloalkyl-fused tetrahydroquinolines of the formula (i), and their pharmaceutically acceptable salts and esters, wherein r1, r2, r7, r8a, e, y, z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
05/08/14
20140127288
Liposome containing pyrroloquinoline quinone and sugar
An object of the present invention is to provide a composition that enables extension of the concentration range in which pyrroloquinoline quinone exerts cell growth-promoting function, and an efficient method of producing the composition. According to the present invention, there is provided a liposome composition comprising liposomes individually containing pyrroloquinoline quinone or a salt thereof and sugar, 50% or more of the liposomes having a particle diameter in the range of from 1 to 10 μm, and a method of producing the composition..
05/01/14
20140116696
Compositions and methods related to mitigating aluminum and ferric precipitates in subterranean formations after acidizing operations
Trivalent-ion chelating agents may be useful in mitigating the formation aluminum and ferric precipitates in subterranean formations during acidizing operations. An acidizing operation may include introducing an acidizing fluid into a wellbore penetrating a subterranean formation, the acidizing fluid comprising an aqueous fluid, an acid source, and a trivalent-ion chelating agent, e.g., hydroxamates, 6,7-dihydroxyquinoline, 3-hydroxy-4-pyridinones, and any combination thereof.
04/24/14
20140113896
Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
The present invention relates to substituted phenoxypyridine compounds of general formula (i); in which r1, r2 and r3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. .
04/24/14
20140113877
Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
In which a, x, r1, r2, r3 and r7 have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.. .
04/24/14
20140112988
Pharmaceutical composition and administrations thereof
The present invention relates to pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.. .
04/24/14
20140112946
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-n methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g.
04/24/14
20140112868
Novel tetrahydroisoquinoline compounds for use in the diagnosis and treatment of neurodegenerative diseases
The invention relates to a new class of compounds with high affinity and selectivity towards p-glycoprotein. The invention also relates to the utilization of such compounds in the in vivo diagnosis of neurodegenerative diseases and as medicaments for use in the prevention and treatment of neurodegenerative disease involving p-glycoprotein..
04/17/14
20140107153
Therapeutic quinoline and naphthalene derivatives
Therapeutic methods, compositions, and medicaments related thereto are also disclosed.. .
04/17/14
20140107127
Pyrazinoisoquinoline compounds
This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
04/17/14
20140103305
5-substituted 2-phenylquinoline complexes materials for light emitting diode
Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a bulky alkyl at the 5-position.
04/10/14
20140100234
Quinoline derivatives as pi3 kinase inhibitors
Invented is a method of inhibiting the activity/function of pi3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives..
03/27/14
20140088130
Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (i) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor.
03/27/14
20140088094
N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting rorγ activity, reducing the amount of il-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.. .
03/27/14
20140088093
Tricyclic tetrahydroquinoline antibacterial agents
Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.. .
03/20/14
20140080867
Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
The invention relates to substituted 2-oxy-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.. .
03/20/14
20140080865
Salts and solvates of a tetrahydroisoquinoline derivative
(s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described..
03/20/14
20140080816
Tricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/20/14
20140080814
Tricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/20/14
20140080813
Tricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/06/14
20140066470
Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy.
03/06/14
20140066469
Treatment of diseases associated with inflammation
Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e.g. Hydroxychloroquine, and a statin, e.g.
03/06/14
20140066459
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
02/27/14
20140058109
Crystal form of quinoline compound and process for its production
The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form a, thereby to obtain a drug substance excellent in stability.. .
02/20/14
20140051723
Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
The subject invention provides deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.. .
02/20/14
20140050696
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention.
02/13/14
20140045834
7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1h-imidazo[4,5-c]quinoline derivatives
Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
02/13/14
20140041133
Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor
The present invention relates to a cosmetic composition for dyeing keratin fibres, in particular human keratin fibres such as the hair, comprising: a) one or more fatty substances; b) one or more surfactants; c) one or more oxidation bases; d) one or more couplers based on 2-hydroxynaphthalene derivatives or particular phenol derivatives, acylaminophenol derivatives or quinoline derivatives; f) one or more basifying agents; e) optionally one or more chemical oxidizing agents; and the fatty substance content representing in total at least 25% by weight relative to the total weight of the formulation. The present invention also relates to a process using this composition, and to a multi-compartment device that is suitable for performing the said process..
02/06/14
20140039006
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline derivatives, pharmaceutical compositions containing such compounds and to their use in therapy.. .
01/30/14
20140031544
Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
Wherein the variables r1, r2, r3, r4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (hsd) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia..
01/30/14
20140031391
Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use
The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.. .
01/30/14
20140031336
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and their use in therapy.. .
01/30/14
20140031276
Compounds and methods for preventing or treating a viral infection
A compound is provided which has a structure i: a-b-c and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which a is a quinoline or quinoline-like group, b is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and c is an o-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be q-vd-oph (n-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an o-methylated form.
01/23/14
20140024678
Stable laquinimod preparations
The subject invention provides a pharmaceutical composition comprising n-ethyl-n-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to n-ethyl-n-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-chloro-6-(1-ethyl-n-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1h,3h-spiro[5-chloro-1-methylquinoline-2,4 -dione-3,3′-[1]ethylindolin-[2]-one], or 5-chloro-n-ethyl-3-hydroxy-1-methyl-2,4-dioxo-n-phenyl-1,2,3,4 -tetrahydro-quinoline-3-carboxamide.. .
01/23/14
20140024676
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
01/23/14
20140024675
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .


Popular terms: [SEARCH]

Quinoline topics: Isoquinolin, Praziquantel, Carbon Atoms, Crystallin, Quinoline Derivatives, Pharmaceutically Acceptable Salt, Alkyl Group, Cycloalkyl, Pharmaceutically Acceptable Salts, Immunodeficiency, Retrovirus, Viral Infection, Human Immunodeficiency Virus, Angiogenesis, Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3302

3435

1 - 1 - 73